The role of protease activated receptors on platelets

蛋白酶激活受体对血小板的作用

基本信息

  • 批准号:
    10319016
  • 负责人:
  • 金额:
    $ 47.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-08-15 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Venous thrombosis (VT) and its major complication, pulmonary embolism (PE), are often grouped together and called venous thromboembolism (VTE). VTE is a major health problem that affect nearly 600,000 people each year. The historical drivers of VTE are blood stasis, endothelial dysfunction, and hypercoagulation (Virchow’s triad). It is now recognized that platelets and neutrophils have a critical initiating role. The molecular mechanisms are only being uncovered. Given that hypercoagulation is a risk factor and thrombin activated protease activated receptor 4 (PAR4) promotes procoagulant platelets, phosphatidyl serine (PS) exposure and subsequent thrombin generation, we propose that PAR4 is an important contributor to VTE. The long-term goals of this research program are to uncover the mechanisms of PAR4 activation at the molecular level and test these mechanism in vivo to inform disease processes and potential drug development. The scientific premise of this proposal is based our preliminary data showing that extracellular loop 3 (ECL3) of PAR4 coordinates with the ligand binding site (LBS) during PAR4 activation. Further, mutations in either ECL3 or the LBS disrupt PAR4 signaling to the same degree. This points to an essential role for ECL3 in PAR4 activation. The overall objective of this proposal is to 1) to determine how PAR4 contributes to the initiation and propagation of venous thrombosis using mouse models, 2) conduct proof-of-concept studies using PAR4 antagonist to treat VT, 3) to translate our recent structural insights on the PAR4 activation mechanism to PAR4 function in vivo. We will do this by taking advantage a PAR4 variant in human platelets and a new mouse model. Our overall hypothesis is that the sustained signaling from PAR4 on platelets is a driver of VTE and reduced PAR4 signaling from hypo-reactive variants or pharmacological inhibitors will lead to protection from VTE. Our innovative approach will take advantage of a new mouse model that recreates a polymorphism in ECL3 and will allow us to determine the mechanism of how this polymorphism contributes to platelet function and thrombosis. The completion of the proposed studies will accomplish two major advances. 1) we will be the first to specifically examine the role of PAR4 in venous thrombosis. 2) we will continue to push our basic understanding of PAR activation mechanisms by testing the observations from our structural studies in vivo to determine how these mechanisms operate in physiological and pathophysiological contexts.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marvin Thomas Nieman其他文献

Marvin Thomas Nieman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marvin Thomas Nieman', 18)}}的其他基金

The structural basis for PAR1 biased signaling
PAR1 偏向信号传导的结构基础
  • 批准号:
    10042725
  • 财政年份:
    2020
  • 资助金额:
    $ 47.5万
  • 项目类别:
The structural basis for PAR1 biased signaling
PAR1 偏向信号传导的结构基础
  • 批准号:
    10241452
  • 财政年份:
    2020
  • 资助金额:
    $ 47.5万
  • 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
  • 批准号:
    8274738
  • 财政年份:
    2010
  • 资助金额:
    $ 47.5万
  • 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
  • 批准号:
    8478172
  • 财政年份:
    2010
  • 资助金额:
    $ 47.5万
  • 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
  • 批准号:
    7984232
  • 财政年份:
    2010
  • 资助金额:
    $ 47.5万
  • 项目类别:
The role of protease activated receptors on platelets
蛋白酶激活受体对血小板的作用
  • 批准号:
    9241436
  • 财政年份:
    2010
  • 资助金额:
    $ 47.5万
  • 项目类别:
The role of protease activated receptors on platelets
蛋白酶激活受体对血小板的作用
  • 批准号:
    10579822
  • 财政年份:
    2010
  • 资助金额:
    $ 47.5万
  • 项目类别:
The role of protease activated receptors on platelets
蛋白酶激活受体对血小板的作用
  • 批准号:
    9889979
  • 财政年份:
    2010
  • 资助金额:
    $ 47.5万
  • 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
  • 批准号:
    8125073
  • 财政年份:
    2010
  • 资助金额:
    $ 47.5万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 47.5万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 47.5万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 47.5万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 47.5万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 47.5万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 47.5万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 47.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 47.5万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 47.5万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 47.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了